GlassScriptPhysician profile
Max Hamburger
NPI 1023004876
$322,872.22
in general payments reported to CMS, 2019-2025
36 companies · $931 in 2025
The $931 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,062 · 2020: $350 · 2021: $1,242 · 2022: $288K · 2023: $22K · 2024: $8,666 · 2025: $931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Travel and Lodging: $11K · Food and Beverage: $3,935 · Grant: $1,000 · Honoraria: $350 · Education: $11.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,000.00 |
| Travel and Lodging | $11,015.89 |
| Food and Beverage | $3,934.89 |
| Grant | $1,000.00 |
| Honoraria | $350.00 |
| Education | $11.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sn Holdings, LLC | $166,383.38 | 2022-2024 | |
| Abbvie INC. | $147,653.68 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,536.67 | 2019-2025 | |
| Amgen INC. | $1,245.25 | 2019-2025 | Tavneos, Krystexxa, Enbrel |
| Janssen Biotech, INC. | $1,034.77 | 2019-2025 | Tremfya |
| Ucb, INC. | $604.25 | 2019-2025 | Cimzia, Bimzelx |
| Horizon Therapeutics Plc | $587.63 | 2019-2023 | Krystexxa |
| Lilly USA, LLC | $546.51 | 2019-2024 | Taltz |
| Pfizer INC. | $378.75 | 2019-2025 | |
| Fidia Pharma USA INC. | $350.31 | 2019-2025 | Hym/Hyn, Hymhyn |
| Boehringer Ingelheim Pharmaceuticals, INC. | $278.24 | 2022-2025 | Ofev, Cyltezo |
| Ani Pharmaceuticals, INC. | $266.70 | 2022-2024 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $218.60 | 2022-2024 | Lupkynis |
| US Oncology Corporate, INC. | $156.42 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $145.21 | 2019-2025 | Orencia |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $140.56 | 2019-2025 | Actemra |
| Glaxosmithkline, LLC. | $140.07 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $138.80 | 2021-2024 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $120.16 | 2022-2023 | Acthar |
| Antares Pharma, INC. | $110.20 | 2019 | |
| Radius Health, INC. | $104.93 | 2019-2025 | Tymlos |
| Merck Sharp & Dohme LLC | $97.87 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $81.02 | 2023 | Uptravi |
| Genzyme Corporation | $71.29 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $66.49 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $64.68 | 2019 | |
| Sobi, INC | $58.10 | 2023 | |
| Medexus Pharma, INC. | $47.04 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $43.76 | 2024 | |
| Celgene Corporation | $42.82 | 2019 | |
| Sandoz INC. | $34.48 | 2023 | Hyrimoz |
| Janssen Pharmaceuticals, INC | $32.23 | 2025 | Tremfya |
| Almatica Pharma LLC | $31.51 | 2025 | Teriparatide |
| Ferring Pharmaceuticals INC. | $23.08 | 2022 | |
| Pacira Therapeutics, INC. | $21.76 | 2019 | |
| Janssen Scientific Affairs, LLC | $15.00 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$7,980,533.49 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Hamburger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.